Edition:
United Kingdom

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

84.80USD
6:14pm GMT
Change (% chg)

$0.62 (+0.74%)
Prev Close
$84.18
Open
$84.44
Day's High
$85.69
Day's Low
$82.15
Volume
76,562
Avg. Vol
272,501
52-wk High
$126.15
52-wk Low
$68.44

Latest Key Developments (Source: Significant Developments)

Neurocrine Biosciences And Jnana Therapeutics Enter Into Strategic Collaboration
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES AND JNANA THERAPEUTICS ENTER STRATEGIC COLLABORATION TO DISCOVER NOVEL MEDICINES TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS.NEUROCRINE BIOSCIENCES - UNDER TERMS OF AGREEMENT, NEUROCRINE AND JNANA WILL WORK JOINTLY TO IDENTIFY NOVEL COMPOUNDS.  Full Article

AbbVie Announces Positive Results From Phase 3 Study Evaluating Investigational Elagolix
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 EXTENSION STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS.ABBVIE INC - RESULTS WERE CONSISTENT WITH TWO PIVOTAL PHASE 3 STUDIES (ELARIS UF-I AND ELARIS UF-II) AND NO NEW SAFETY SIGNALS WERE IDENTIFIED.ABBVIE INC - STUDY RESULTS SHOWED ELAGOLIX, IN COMBINATION WITH ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING FOR UP TO 12 MONTHS.ABBVIE - DATA FROM PHASE 3 PROGRAM WILL SUPPORT REGULATORY SUBMISSION FOR ELAGOLIX IN UTERINE FIBROIDS, ANTICIPATED IN 2019.ABBVIE INC - SECONDARY ENDPOINT RESULTS IN EXTENSION STUDY WERE ALSO CONSISTENT WITH THAT OBSERVED IN PIVOTAL STUDIES.  Full Article

Neurocrine Biosciences Q2 Loss Per Share $0.07
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.07.Q2 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.QUARTERLY TOTAL REVENUES $96.91 MILLION VERSUS $6.34 MILLION.  Full Article

Neurocrine Biosciences Says $40 Mln Event-Based Payment To Be Made To Co By Abbvie
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Neurocrine Bioscience::NEUROCRINE BIOSCIENCES - WITH FDA APPROVAL OF ORILISSA, $40 MILLION EVENT-BASED PAYMENT WILL BE MADE TO CO BY ABBVIE UNDER COLLABORATION AGREEMENT.NEUROCRINE BIOSCIENCES - $40 MILLION EVENT-BASED PAYMENT BY ABBVIE TO CO TO BE RECOGNIZED AS REVENUE BY CO IN Q3.  Full Article

AbbVie Receives U.S. FDA Approval Of Orilissa
Tuesday, 24 Jul 2018 

July 24 (Reuters) - AbbVie Inc ::ABBVIE RECEIVES U.S. FDA APPROVAL OF ORILISSA™ (ELAGOLIX) FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS.ABBVIE INC - ORILISSA IS EXPECTED TO BE AVAILABLE IN U.S. RETAIL PHARMACIES IN EARLY AUGUST 2018.  Full Article

Neurocrine Biosciences Q1 Loss Per Share $0.47
Monday, 30 Apr 2018 

April 30 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.47.Q1 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.ONGOING OPERATING EXPENSES FOR 2018 ARE NOW EXPECTED TO APPROXIMATE $395 TO $420 MILLION.QTRLY TOTAL REVENUES $71.1 MILLION.Q1 REVENUE VIEW $63.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Neurocrine Biosciences appoints Matt Abernethy as CFO
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Neurocrine Biosciences Inc ::Neurocrine Biosciences appoints Matt Abernethy as chief financial officer.Neurocrine Biosciences Inc - announced that Matt Abernethy is joining executive management team as chief financial officer​.  Full Article

Neurocrine Biosciences reports Q3 loss per share $0.13
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences reports third quarter 2017 results.Q3 loss per share $0.13.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Says net product sales of $45.8 million for three months ended September 30, 2017​.  Full Article

Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Abbvie Inc :Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain.Abbvie inc - ‍expects PDUFA date for FDA to complete its review will be in Q2 2018​.  Full Article

Neurocrine initiates Phase IIb clinical study of Ingrezza
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Neurocrine Biosciences Inc :Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome.Neurocrine Biosciences Inc - ‍top-line data from study is expected in late 2018​.  Full Article

AbbVie prices new endometriosis drug at $10,000 a year

NEW YORK, July 24 Drugmaker AbbVie Inc priced its new endometriosis drug Orilissa at around $10,000 a year after receiving approval from U.S. regulators for the treatment on Tuesday.